Oncology Focused Investment Comes Into Its Own
Executive Summary
UBS closed its $471m Oncology Impact Fund, a specialist investment vehicle for early stage oncology, in April this year. But it was by no means the first commercial investment vehicle to focus solely on oncology. Nextech Invest raised its fourth oncology fund in July this year.
You may also be interested in...
Roche Commits Up To $1bn For Blueprint's Immunokinase Inhibitors
When Blueprint Medicines Corp. sought a partner to help advance its kinase inhibitors with the potential to boost immune responses to cancer, the company came up with a short list of ideal big pharma collaborators and Roche rose to the top.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.